Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Status:
NOT_YET_RECRUITING
Trial end date:
2029-10-30
Target enrollment:
Participant gender:
Summary
Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.
Phase:
PHASE3
Details
Lead Sponsor:
University Hospital, Tours
Collaborators:
AP-HP, Hpital Henri Mondor AP-HP, Hpital Paul Brousse AP-HP, Hpital Piti- Salptrire AP-HP, Hpital Saint-Louis Central Hospital, Nancy, France Centre Hospitalier Universitaire Dijon Centre Hospitalier Universitaire, Amiens CHG de St-Malo CHU DE BESANCON CHU de Brest CHU de Clermont-Ferrand CHU de Reims Gustave Roussy, Cancer Campus, Grand Paris HCL Hpital Edouard Hriot Hpital Priv Jean Mermoz Institut Paoli-Calmettes Nantes University Hospital Poitiers University Hospital Polyclinique de Blois Rennes University Hospital University Hospital, Caen University Hospital, Rouen University Hospital, Toulouse